6505--596-24-1-025-0002 - Radiopharmaceutical-LEX - FY24

Closed Solicitation Posted Jul 28, 2023

This opportunity was awarded. See the award notice from Oct 3, 2023.

Solicitation number: 36C24923Q0449
Agency: Veterans Integrated Service Network 9 Veterans Health Administration, Department of Veterans Affairs
Responses due: Aug 18, 2023, 5:00 PM ET
Set-aside: No set-aside

Opportunity facts

NAICS code: 325412 Pharmaceutical Preparation Manufacturing
PSC: 6505 Drugs And Biologicals

Notice details come from SAM.gov. Updated Jul 28, 2023.

About this opportunity

Written by GovTribe AI · Jul 28, 2023

The Memphis VA Medical Center is seeking to purchase various radiopharmaceuticals for a base period of 12 months with four 12-month options. The solicitation includes a wide range of radiopharmaceuticals, including F-18 FDG, Ga-67, I-123, I-131, In-111, PYP Vial, Kinevac (CCK), Tc-99m, Tl-201, and Hot Lab Management Software. The RFQ closes on August 18, 2023, and the award will be based on a comparative evaluation of quotes, with the award going to the response most advantageous to the Government.

Products and Services to be provided:

Various radiopharmaceuticals including F-18 FDG, Ga-67, I-123, I-131, In-111, PYP Vial, Kinevac (CCK), Tc-99m, Tl-201.
The quantities of each product are estimated and listed in the solicitation.
The vendor must be able to provide all items to be considered responsive.
The contract includes a base period of 12 months with four 12-month options.
Hot Lab Management Software.

Notice text

Description

This is a solicitation for commercial products and commercial services prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, Streamlined Procedures for Evaluation and Solicitation for Commercial Products and Commercial Services, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested, and a written solicitation document will not be issued.

This solicitation is issued as an RFQ. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular FAC 2023-01, effective December 30, 2022.

This solicitation is for Full and Open competition.

The associated North American Industrial Classification System (NAICS) code for this procurement is 325412, with a small business size standard of 1,300 employees.

The FSC/PSC is 6505.

The Memphis VA Medical Center is seeking to purchase various radiopharmaceuticals for a Base period of 12 months plus four (4) 12-month options.

All interested companies shall provide quotations for the following:

Vendor MUST be able to provide ALL items in order to be determined responsive. All quantities are ESTIMATED.

Supplies/Services

Item Number

Description

ESTIMATED Quantity

Unit of Measure

Unit Price

Extended Price

0001

F-18 FDG 10mCi

400

0002

Ga-67 (per mCi)

0003

I-123 200uCi Uptake Caps

0004

I-131 Diagnostic Cap (5mCi)

0005

I-131 Therapeutic dose (per mCi) physician ordered

1200

0006

I-131 Uptake Caps .02mCi

0007

In-111 Octreoscan (pentatreotide) 6mCi

0008

In-111 WBC Kit/Labeling 1mCi

0009

PYP Vial

0010

Kinevac (CCK)

0011

Tc-99m Exametazime * 25mCi

0012

Tc-99m HMPAO WBC Kit/Labeling 20mCi

0013

Tc-99m Macroaggregated Albumin (MAA) 3mCi

0014

Tc-99m Mebrofenin (Choletec) 5mCi

0015

Tc-99m Medronate (MDP) 25mCi

250

0016

Tc-99m MAG3 (mertiatide) 6mCi

0017

Tc-99m Pentetate (DTPA) 30mCi

0018

Tc-99m pyrophosphate (Hot PYP) 20mCi

0019

Tc-99m sestamibi 25mCi

0020

Tc-99m sodium pertechnetate (TcO4) 20mCi

0021

Tc-99m sulfur colloid dmCi

0022

Tc-99m sulfur colloid filtered 1mCi

0023

Tc-99m TcO4 LINEARITY SOURCE 300mCi

0024

Tc-99m Myoview 15mCi

1500

0025

Tl-201 (per mCi) 4mCi

0026

Tc-99m UltraTag Kit

0027

Hot Lab Management Software

1001

F-18 FDG 10mCi

400

1002

Ga-67 (per mCi)

1003

I-123 200uCi Uptake Caps

1004

I-131 Diagnostic Cap (5mCi)

1005

I-131 Therapeutic dose (per mCi) physician ordered

1200

1006

I-131 Uptake Caps .02mCi

1007

In-111 Octreoscan (pentatreotide) 6mCi

1008

In-111 WBC Kit/Labeling 1mCi

1009

PYP Vial

1010

Kinevac (CCK)

1011

Tc-99m Exametazime * 25mCi

1012

Tc-99m HMPAO WBC Kit/Labeling 20mCi

1013

Tc-99m Macroaggregated Albumin (MAA) 3mCi

1014

Tc-99m Mebrofenin (Choletec) 5mCi

1015

Tc-99m Medronate (MDP) 25mCi

250

1016

Tc-99m MAG3 (mertiatide) 6mCi

1017

Tc-99m Pentetate (DTPA) 30mCi

1018

Tc-99m pyrophosphate (Hot PYP) 20mCi

1019

Tc-99m sestamibi 25mCi

1020

Tc-99m sodium pertechnetate (TcO4) 20mCi

1021

Tc-99m sulfur colloid dmCi

1022

Tc-99m sulfur colloid filtered 1mCi

1023

Tc-99m TcO4 LINEARITY SOURCE 300mCi

1024

Tc-99m Myoview 15mCi

1500

1025

Tl-201 (per mCi) 4mCi

1026

Tc-99m UltraTag Kit

1027

Hot Lab Management Software

2001

F-18 FDG 10mCi

400

2002

Ga-67 (per mCi)

2003

I-123 200uCi Uptake Caps

2004

I-131 Diagnostic Cap (5mCi)

2005

I-131 Therapeutic dose (per mCi) physician ordered

1200

2006

I-131 Uptake Caps .02mCi

2007

In-111 Octreoscan (pentatreotide) 6mCi

2008

In-111 WBC Kit/Labeling 1mCi

2009

PYP Vial

2010

Kinevac (CCK)

2011

Tc-99m Exametazime * 25mCi

2012

Tc-99m HMPAO WBC Kit/Labeling 20mCi

2013

Tc-99m Macroaggregated Albumin (MAA) 3mCi

2014

Tc-99m Mebrofenin (Choletec) 5mCi

2015

Tc-99m Medronate (MDP) 25mCi

250

2016

Tc-99m MAG3 (mertiatide) 6mCi

2017

Tc-99m Pentetate (DTPA) 30mCi

2018

Tc-99m pyrophosphate (Hot PYP) 20mCi

2019

Tc-99m sestamibi 25mCi

2020

Tc-99m sodium pertechnetate (TcO4) 20mCi

2021

Tc-99m sulfur colloid dmCi

2022

Tc-99m sulfur colloid filtered 1mCi

2023

Tc-99m TcO4 LINEARITY SOURCE 300mCi

2024

Tc-99m Myoview 15mCi

1500

2025

Tl-201 (per mCi) 4mCi

2026

Tc-99m UltraTag Kit

2027

Hot Lab Management Software

3001

F-18 FDG 10mCi

400

3002

Ga-67 (per mCi)

3003

I-123 200uCi Uptake Caps

3004

I-131 Diagnostic Cap (5mCi)

3005

I-131 Therapeutic dose (per mCi) physician ordered

1200

3006

I-131 Uptake Caps .02mCi

3007

In-111 Octreoscan (pentatreotide) 6mCi

3008

In-111 WBC Kit/Labeling 1mCi

3009

PYP Vial

3010

Kinevac (CCK)

3011

Tc-99m Exametazime * 25mCi

3012

Tc-99m HMPAO WBC Kit/Labeling 20mCi

3013

Tc-99m Macroaggregated Albumin (MAA) 3mCi

3014

Tc-99m Mebrofenin (Choletec) 5mCi

3015

Tc-99m Medronate (MDP) 25mCi

250

3016

Tc-99m MAG3 (mertiatide) 6mCi

3017

Tc-99m Pentetate (DTPA) 30mCi

3018

Tc-99m pyrophosphate (Hot PYP) 20mCi

3019

Tc-99m sestamibi 25mCi

3020

Tc-99m sodium pertechnetate (TcO4) 20mCi

3021

Tc-99m sulfur colloid dmCi

3022

Tc-99m sulfur colloid filtered 1mCi

3023

Tc-99m TcO4 LINEARITY SOURCE 300mCi

3024

Tc-99m Myoview 15mCi

1500

3025

Tl-201 (per mCi) 4mCi

3026

Tc-99m UltraTag Kit

3027

Hot Lab Management Software

4001

F-18 FDG 10mCi

400

4002

Ga-67 (per mCi)

4003

I-123 200uCi Uptake Caps

4004

I-131 Diagnostic Cap (5mCi)

4005

I-131 Therapeutic dose (per mCi) physician ordered

1200

4006

I-131 Uptake Caps .02mCi

4007

In-111 Octreoscan (pentatreotide) 6mCi

4008

In-111 WBC Kit/Labeling 1mCi

4009

PYP Vial

4010

Kinevac (CCK)

4011

Tc-99m Exametazime * 25mCi

4012

Tc-99m HMPAO WBC Kit/Labeling 20mCi

4013

Tc-99m Macroaggregated Albumin (MAA) 3mCi

4014

Tc-99m Mebrofenin (Choletec) 5mCi

4015

Tc-99m Medronate (MDP) 25mCi

250

4016

Tc-99m MAG3 (mertiatide) 6mCi

4017

Tc-99m Pentetate (DTPA) 30mCi

4018

Tc-99m pyrophosphate (Hot PYP) 20mCi

4019

Tc-99m sestamibi 25mCi

4020

Tc-99m sodium pertechnetate (TcO4) 20mCi

4021

Tc-99m sulfur colloid dmCi

4022

Tc-99m sulfur colloid filtered 1mCi

4023

Tc-99m TcO4 LINEARITY SOURCE 300mCi

4024

Tc-99m Myoview 15mCi

1500

4025

Tl-201 (per mCi) 4mCi

4026

Tc-99m UltraTag Kit

4027

Hot Lab Management Software

Total

All quoters shall submit the following:

Technical or Quality: Provide the extent to which the proposed item(s) can meet and/or exceed the Government s requirements as outlined in the solicitation and based on the information requested in the instructions to quoters section of the solicitation.

Past Performance: Provide verifiable past performance evaluations - minimum of 2, maximum of 3 - of similar contracts performed. The past performance evaluation will assess the relative risks associated with a quoter s likelihood of success in fulfilling the solicitation s requirements as indicated by the quoter s record of past performance. The past performance evaluation may be based on the contracting officer s knowledge of and previous experience with the supply or service being acquired; Customer surveys, and past performance questionnaire replies; Contractor Performance Assessment Reporting System (CPARS) at http://www.cpars.gov/; or any other reasonable basis.

Price: The Government will evaluate the price by adding the total of all line item prices.

-Options. The Government will evaluate quotations for award purposes by adding the total price for all options to the total price for the basic requirement. This includes options under FAR 52.217-8, Option to Extend Services, which applies to this solicitation. Evaluation of options under FAR 52.217-8 will be accomplished by adding six months of the quoter's price for the last potential period of performance under this contract to the quoter's total price.Â For example, if the contract includes option periods that are exercisable under FAR 52.217-9, the quoter's total price for the purpose of evaluation will include the base period, all option periods, and an additional six months of the last option period. Quoters must price only the base and option periods specified in the contract line item numbers (CLINs), and shall not submit a price for the potential six-month extension of services under FAR 52.217-8. The Government reserves the right to exercise the option under FAR 52.217-8 before the end of any of the contractor's performance periods and will be exercised at the price and/or rates in effect at the time the clause is exercised. Evaluation of options shall not obligate the Government to exercise the option(s).

-36C24923Q0449 Line Item Spreadsheet (attached) with all columns highlighted in yellow completed.

All quotes shall be sent to Martha.Warren1@va.gov.

Award will be based upon a comparative evaluation of quotes in accordance with the Simplified Acquisition Procedures of FAR 13. Comparative evaluation is the side by side pairwise comparison of quotes based on factors resulting in a Contracting Officer decision for the quote most favorable to the Government.

The award will be made to the response most advantageous to the Government.

Responses should contain your best terms, conditions.

Additional Solicitation Terms and Conditions.

This is a Full and Open Competition solicitation.

This RFQ closes August 18, 2023, at 16:00 CDT. Submit all quotes and applicable attachments by e-mail to martha.warren1@va.gov with subject line RFQ 36C24923Q0449 Radiopharmaceuticals-LEX by Friday, August 18, 2023, at 16:00 hours (CDT).

Final Offer package will be put into attachments and emailed to martha.warren1@va.gov.

Multiple emails will not be accepted.

Our email server has a size limitation of 30 GB. Zip files will be removed and therefore, will not be considered.

Email attachment must be in .pdf format and in the English language. Font type & size must be appropriate for easy and quick viewing, 10 point or greater. Only acceptable font types are Calibri, Times New Roman, Courier, or Arial. Documents must only be 8 Â½ x 10 inches in size, with one-inch margins all around.

Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f).

Must include offer s UEI Unique Entity Identification

To facilitate the award process, all quotes must include a statement regarding the terms and conditions herein as follows:

"The terms and conditions in the solicitation are acceptable to be included in the award document without modification, deletion, or addition."

"The terms and conditions in the solicitation are acceptable to be included in the award document with the exception, deletion, or addition of the following:"

Quoter shall list exception(s) and rationale for the exception(s).

Phone calls and fax will not be accepted, all questions or concerns must be submitted via email to martha.warren1@va.gov, with subject line Questions- RFQ 36C24923Q0449 Radiopharmaceuticals-LEX by Friday, August 11, 2023, at 16:00 hours (CDT).

The Government reserves the right to make no award at all.

Files

File	Type	Posted
36C24923Q0449_1.docx	DOCX document	Jul 28, 2023
36C24923Q0449 LineItems.xlsx	XLSX spreadsheet	Jul 28, 2023

Notice history

Notice	Type	Posted
6505--596-24-1-025-0002 - Radiopharmaceutical Package Base plus 4 Options Award	Award Notice	Oct 3, 2023
This notice Latest solicitation	Solicitation	Jul 28, 2023
6505--596-24-1-025-0002 - Radiopharmaceutical-LEX - FY24 Original	Pre-Solicitation	Jul 6, 2023

Similar open opportunities

Opportunity	Agency	Set-aside	Responses due
6505--Radiopharmaceuticals Base Plus Four Option Years VA San Diego Healthcare System Department of Veterans Affairs VA San Diego Healthcare System San Diego CA 92161 · NAICS 325412	Veterans Integrated Service Network 22	No set-aside	Nov 6, 2026
6505--Sources Sought VISN2 DOWNSTATE GENERAL RADIOPHARMACEUTICALS Visn 2 Downstate, United States · NAICS 325412	Veterans Integrated Service Network 2	No set-aside	Nov 17, 2026
6505--General Radioisotopes (Diagnostic & Therapeutic) Department of Veteran Affairs Salt Lake City VA Medical Center Salt Lake City, Utah 84148, United States · NAICS 325412	Veterans Integrated Service Network 19	No set-aside	Nov 12, 2026
6515--Thyroid Uptake System in Support of the Iowa City VA Healthcare System, Iowa City, IA. 100% Set-Aside for SDVOSBs. Department of Veterans Affairs Iowa City VA Health Care System Iowa City, Iowa 52246, United States · NAICS 334517	Veterans Integrated Service Network 23	Service-Disabled Veteran-Owned Small Business	Nov 13, 2026

On GovTribe

Work this opportunity

Track it in your pipeline
Find teaming partners
Similar opportunities
Ask GovTribe AI about this opportunity

Try for free Login

GovTribe for Federal Contractors